专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015120440A2 CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES 审中-公开
标题翻译： CD4-模拟小分子增强人免疫缺陷病毒对疫苗诱导的抗体的敏感性
公开(公告)号：WO2015120440A2
公开(公告)日：2015-08-13
申请号：PCT/US2015/015182
申请日：2015-02-10
申请人： DANA-FARBER CANCER INSTITUTE, INC. , THE JOHNS HOPKINS UNIVERSITY , BRYN MAWR COLLEGE , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , THE SCRIPPS RESEARCH INSTITUTE
发明人： SODROSKI, Joseph , MADANI, Navid , PRINCIOTTO, Amy, M. , SCHON, Ame , LALONDE, Judith, M. , FREIRE, Ernesto , SMITH, Amos, B., III , WYATT, Richard, T. , PARK, Jongwoo , COURTER, Joel, R. , JONES, David, M.
IPC分类号： A61K31/165
CPC分类号： C07K16/1063 , A61K31/167 , A61K31/438 , A61K31/4468 , A61K39/42 , A61K2039/505 , C07D211/56 , C07K16/2812 , C07K2317/32 , C07K2317/732 , C07K2317/76 , A61K2300/00
摘要： Described herein are methods of generating a protein binding domain that specifically binds to gp120 in a specific conformational state, comprising contacting gp120 with a CD4-mimetic compound, thereby forming gp120 in the specific conformational state; and generating antibodies to gp120 in the specific conformation state. Relatedly, the disclosure also describes methods of neutralizing HIV- 1, comprising contacting HIV-1 with an effective amount of a CD4-mimetic compound, thereby forming HIV-1 having gp120 in a specific conformational state; and contacting the HIV-1 in the specific conformational state with an antibody.
摘要翻译：本文描述了产生特异性结合gp120的蛋白质结合结构域的方法，所述蛋白质结合结构域以特定构象状态与gp120特异性结合，所述方法包括使gp120与CD4模拟化合物接触，由此形成处于特定构象状态的gp120; 并在特定构象状态下产生对gp120的抗体。相关地，本公开还描述了中和HIV-1的方法，包括使HIV-1与有效量的CD4模拟化合物接触，从而形成具有处于特定构象状态的gp120的HIV-1; 并将HIV-1以特定的构象状态与抗体接触。

2. 发明申请

WO2013090696A1 CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF 审中-公开
标题翻译： HIV-1入侵的CD4-物质抑制剂及其使用方法
公开(公告)号：WO2013090696A1
公开(公告)日：2013-06-20
申请号：PCT/US2012/069708
申请日：2012-12-14
申请人： DANA-FARBER CANCER INSTITUTE, INC. , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIECES , BRYN MAWR COLLEGE , THE JOHNS HOPKINS UNIVERSITY , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人： SODROSKI, Joseph , LALONDE, Judith, M. , SMITH, Amos, B., iii , KWONG, Peter, D. , KWON, Young Do , JONES, David, M. , SUN, Alexander, W. , COURTER, Joel, R. , SOETA, Takahiro , KOBAYASHI, Toyoharu , PRINCIOTTO, Amy M. , WU, Xueling , MASCOLA, John R. , SCHON, Arne , FREIRE, Ernesto , MADANI, Navid , LE-KHAC, Matthew , HENDRICKSON, Wayne, A.
IPC分类号： A01N25/00
CPC分类号： C07C279/16 , A61K31/167 , A61K31/185 , C07C233/56 , C07C237/06 , C07C237/22 , C07C279/12 , C07C2601/14 , C07C2602/08 , C07D207/335 , C07D207/34 , C07D209/88 , C07D209/94 , C07D233/88 , C07D235/02 , C07D235/06 , C07D271/07 , C07D307/52
摘要： Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gpl20, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD- 556.
摘要翻译：本文描述的是CD4的小分子模拟物，其都进入HIV-1包膜蛋白的gp2020的Phe43空穴和靶标Asp368。本文还描述了使用这些化合物抑制HIV感染的传播或进展的方法。这些化合物显示出比已知的抗病毒剂NBD-556的抗病毒效力更大，对于进化枝B和C病毒具有100％的广度。重要的是，与NBD-556相反，化合物不能激活CD4阴性CCR5阳性细胞的HIV感染。

3. 发明申请

WO2016025681A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF 审中-公开
标题翻译： HIV-1进入的抑制剂及其使用方法
公开(公告)号：WO2016025681A1
公开(公告)日：2016-02-18
申请号：PCT/US2015/044998
申请日：2015-08-13
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , DANA-FARBER CANCER INSTITUTE, INC.
发明人： SMITH, Amos, B. III , SODROSKI, Joseph , MADANI, Navid , MELILLO, Bruno
IPC分类号： C07C233/06 , C07C237/40 , C07C279/12
CPC分类号： C07C279/12 , A61K31/167 , A61K39/42 , C07C2602/08 , C07K14/005 , C07K16/1063 , C12N7/00 , C12N2740/16122
摘要： The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.
摘要翻译：本公开提供了使初级HIV-1（包括透射/创始病毒）致敏的单克隆抗体（例如针对CD4诱导的（CD4i）表位和V3区的那些）中和的组合物和方法。在某些实施方案中，本公开涉及使用小分子作为杀微生物剂直接抑制HIV-1感染并使初级HIV-1对容易引发的抗体的中和敏感。

4. 发明申请

WO2007030518A3 CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS AND TRIGGERING HIV-1 ENVELOPE TO REVEAL CRYPTIC V3-LOOP EPITOPES 审中-公开
公开(公告)号：WO2007030518A3
公开(公告)日：2007-03-15
申请号：PCT/US2006/034681
申请日：2006-09-06
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , DANA FARBER CANCER INSTITUTE, INC. , KWONG, Peter , MASCOLA, John , NABEL, Gary , WYATT, Richard , DEY, Barna , XU, Ling , ZHOU, Tongqing , HUANG, Chih-Chin , SODROSKI, Joseph , YUAN, Wen , XIANG, Shi-Hua
发明人： KWONG, Peter , MASCOLA, John , NABEL, Gary , WYATT, Richard , DEY, Barna , XU, Ling , ZHOU, Tongqing , HUANG, Chih-Chin , SODROSKI, Joseph , YUAN, Wen , XIANG, Shi-Hua
IPC分类号： C07K14/16
摘要： Stabilized forms of gpl20 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gpl20, and gpl20 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.

5. 发明申请

WO2015171995A1 SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF 审中-公开
标题翻译： HIV-1入侵小分子抑制剂及其使用方法
公开(公告)号：WO2015171995A1
公开(公告)日：2015-11-12
申请号：PCT/US2015/029846
申请日：2015-05-08
申请人： DANA-FARBER CANCER INSTITUTE, INC.
发明人： SODROSKI, Joseph , HERSCHHORN, Alon , GU, Christopher
IPC分类号： A61P31/18 , C07D213/77 , C07D207/36
CPC分类号： C07D417/12 , C07D207/36 , C07D213/77 , C07D285/14
摘要： Described herein are small-molecule compounds that specifically inhibit a wide range of HIV-1 isolates without interfering with CD4 or CCR5 binding. Methods of using die compounds for treating or preventing HIV infection are also described.
摘要翻译：本文描述的是特异性抑制大范围HIV-1分离物而不干扰CD4或CCR5结合的小分子化合物。还描述了使用模具化合物治疗或预防HIV感染的方法。

6. 发明申请

WO2005081911A2 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α 审中-公开
标题翻译：使用TRIM5α治疗和预防艾滋病毒感染的方法和组合物
公开(公告)号：WO2005081911A2
公开(公告)日：2005-09-09
申请号：PCT/US2005/005458
申请日：2005-02-17
申请人： DANA-FARBER CANCER INSTITUTE, INC. , SODROSKI, Joseph , STREMLAU, Matthew , OWENS, Christopher, M.
发明人： SODROSKI, Joseph , STREMLAU, Matthew , OWENS, Christopher, M.
CPC分类号： C07K14/705 , C12Q1/701 , C12Q1/703
摘要： The invention provides novel TRIM polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length TRIM proteins, the invention further provides isolated TRIM fusion proteins, antigenic peptides and anti- TRIM antibodies. The invention also provides TRIM nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an TRIM gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of viral infection and/or replication, e.g ., HIV infection. The invention further provides methods for identifying a compound capable of treating or preventing viral infection and/or replication, e.g., HIV infection and AIDS. In addition, the invention provides a method for treating a subject having a viral infection and/or replication, e.g ., HIV infection using the modulators of the invention.
摘要翻译：本发明提供了新的TRIM多肽，蛋白质和核酸分子。除了分离的全长TRIM蛋白质外，本发明还提供分离的TRIM融合蛋白，抗原肽和抗TRIM抗体。本发明还提供了TRIM核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞和已引入或破坏了TRIM基因的非人转基因动物。本发明还提供了用于诊断和治疗病毒感染和/或复制（例如HIV感染）的方法和组合物。本发明还提供了鉴定能够治疗或预防病毒感染和/或复制的化合物，例如HIV感染和AIDS的方法。此外，本发明提供了使用本发明的调节剂治疗患有病毒感染和/或复制（例如HIV感染）的受试者的方法。

7. 发明申请

WO2014172366A1 V3 IMMUNOGENS 审中-公开
标题翻译： V3免疫
公开(公告)号：WO2014172366A1
公开(公告)日：2014-10-23
申请号：PCT/US2014/034189
申请日：2014-04-15
申请人： DUKE UNIVERSITY , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , DANA-FARBER CANCER INSTITUTE, INC
发明人： HAYNES, Barton, F. , LIAO, Hua-xin , DANISHEFSKY, Samuel , PARK, Peter , SODROSKI, Joseph , AUSSEDAT, Baptiste , VOHRA, Yusuf
IPC分类号： C07K19/00 , C07K14/00 , G01N33/53 , A61P31/18
CPC分类号： A61K39/12 , A61K2039/545 , A61K2039/55566 , C07K14/001 , C07K14/005 , C07K14/162 , C12N2740/16034 , C12N2740/16134 , G01N33/56988 , G01N2333/16
摘要： The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.
摘要翻译：本发明一般涉及人类免疫缺陷病毒（HIV），特别涉及包含合成V3糖肽的HIV-1疫苗，以及制备和使用它们的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式